These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30516116)

  • 1. Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature.
    Serra W; Fantin A; Longo C; Rabia G; De Rosa F; Plenteda C; Re F; Crisafulli E; Chetta A
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(3):253-258. PubMed ID: 30516116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
    Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
    Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Carfilzomib-Associated Cardiac Adverse Events.
    Mikhael J
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
    Bishnoi R; Xie Z; Shah C; Bian J; Murthy HS; Wingard JR; Farhadfar N
    Cancer Med; 2021 Jan; 10(1):70-78. PubMed ID: 33169938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.
    Lendvai N; Tsakos I; Devlin SM; Schaffer WL; Hassoun H; Lesokhin AM; Landau H; Korde N; Mailankody S; Smith E; Chung DJ; Koehne G; Shah GL; Alexander A; Patel M; Ballagi A; Grundberg I; Giralt SA; Landgren O
    Leuk Lymphoma; 2018 Aug; 59(8):1981-1985. PubMed ID: 29308691
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
    Shah C; Bishnoi R; Jain A; Bejjanki H; Xiong S; Wang Y; Zou F; Moreb JS
    Leuk Lymphoma; 2018 Nov; 59(11):2557-2569. PubMed ID: 29465266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
    Tjionas H; Gupta AK
    J Oncol Pharm Pract; 2017 Mar; 23(2):152-156. PubMed ID: 26786028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
    Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
    High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
    Mian HS; Fiala MA; Sanchez L; Vij R; Wildes TM
    Ann Hematol; 2021 May; 100(5):1261-1266. PubMed ID: 33475778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.
    Patel VG; Cornell RF
    Curr Oncol Rep; 2019 Mar; 21(4):29. PubMed ID: 30834998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.
    Chari A; Hajje D
    BMC Cancer; 2014 Dec; 14():915. PubMed ID: 25471129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
    Cornell RF; Ky B; Weiss BM; Dahm CN; Gupta DK; Du L; Carver JR; Cohen AD; Engelhardt BG; Garfall AL; Goodman SA; Harrell SL; Kassim AA; Jadhav T; Jagasia M; Moslehi J; O'Quinn R; Savona MR; Slosky D; Smith A; Stadtmauer EA; Vogl DT; Waxman A; Lenihan D
    J Clin Oncol; 2019 Aug; 37(22):1946-1955. PubMed ID: 31188726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.
    Wu P; Oren O; Gertz MA; Yang EH
    Curr Oncol Rep; 2020 Jun; 22(7):66. PubMed ID: 32514632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity with carfilzomib at doses greater than 27 mg/m
    Kim GY; Ahuja T; Papadopoulos J; Cirrone F
    J Oncol Pharm Pract; 2019 Jan; 25(1):229-233. PubMed ID: 28914153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis.
    Latif A; Kapoor V; Lateef N; Ahsan MJ; Usman RM; Malik SU; Ahmad N; Rosko N; Rudoni J; William P; Khouri J; Anwer F
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):30-45. PubMed ID: 33845729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma.
    Cole DC; Frishman WH
    Cardiol Rev; 2018; 26(3):122-129. PubMed ID: 29077585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
    Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
    Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.